No abstract available
MeSH terms
-
Bridged-Ring Compounds / administration & dosage*
-
Bridged-Ring Compounds / adverse effects*
-
Female
-
Humans
-
Janus Kinase 2 / antagonists & inhibitors*
-
Lymphoma / drug therapy*
-
Lymphoma / enzymology*
-
Male
-
Protein Kinase Inhibitors / administration & dosage*
-
Protein Kinase Inhibitors / adverse effects*
-
Pyrimidines / administration & dosage*
-
Pyrimidines / adverse effects*
Substances
-
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
-
Bridged-Ring Compounds
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Janus Kinase 2